John D. Carpten
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.
Year:
2025
Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.
Year:
2025
Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.
Year:
2025
Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.
Year:
2025
Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.
Year:
2025
Triple-negative breast cancer (TNBC) is an aggressive disease that disproportionately affects African American (AA) women. Limited targeted therapeutic options exist for patients with TNBC. Here, we employ spatial transcriptomics to interrogate tissue from a racially diverse TNBC cohort to comprehensively annotate the transcriptional states of spatially resolved cellular populations. A total of 38,706 spatial features from a cohort of 28 sections from 14 patients were analyzed. Intratumoral analysis of spatial features from individual sections revealed heterogeneous transcriptional substructures. However, integrated analysis of all samples resulted in nine transcriptionally distinct clusters that mapped across all individual sections. Furthermore, novel use of join count analysis demonstrated nonrandom directional spatial dependencies of the transcriptionally defined shared clusters, supporting a conserved spatio-transcriptional architecture in TNBC. These findings were substantiated in an independent validation cohort comprising 17,861 spatial features representing 15 samples from 8 patients. Stratification of samples by race revealed race-associated differences in hypoxic tumor content and regions of immune-rich infiltrate. Overall, this study combined spatial and functional molecular analyses to define the tumor architecture of TNBC, with potential implications in understanding TNBC disparities. Significance: Spatial transcriptomics profiling of a diverse cohort of triple-negative breast cancers and innovative informatics approaches reveal a conserved cellular architecture across cancers and identify proportional differences in tumor cell composition by race.
Year:
2025
Colorectal cancer (CRC) has increased at an alarming rate amongst younger (< 50 years) individuals. Such early-onset colorectal cancer (EOCRC) has been particularly notable within the Hispanic/Latino population. Yet, this population has not been sufficiently profiled in terms of two critical elements of CRC -- the MYC proto-oncogene and WNT signaling pathway. Here, we performed a comprehensive multi-omics analysis on 30 early-onset and 37 late-onset CRC (≥ 50 years) samples from Hispanic/Latino patients. Our analysis included DNA exome sequencing for somatic mutations, somatic copy number alterations, and global and local genetic similarity. Using RNA sequencing, we also assessed differential gene expression, cellular pathways, and gene fusions. We then compared our findings from early-onset Hispanic/Latino patient samples with publicly available data from Non-Hispanic White cohorts. Across all early-onset patients, which had a median 1000 Genomes Project Peruvian-in-Lima-like (1KG-PEL-like) genetic similarity proportion of 60%, we identified 41 WNT pathway genes with significant mutations. Six important examples were APC, TCF7L2, DKK1, DKK2, FZD10, and LRP5. Notably, patients with mutations in DKK1 and DKK2 had the highest 1KG-PEL-like proportion (79%). When we compared the Hispanic/Latino cohort to the Non-Hispanic White cohorts, four of these key genes -- DKK1, DKK2, FZD10, and LRP5 -- were significant in both risk association analyses and differential gene expression. Interestingly, early-onset tumors (vs. late-onset) exhibited distinct somatic copy number alterations and gene expression profiles; the differences included MYC and drug-targetable WNT pathway genes. We also identified a novel WNT gene fusion, RSPO3, in early-onset tumors; it was associated with enhanced WNT signaling. This integrative analysis underscores the distinct molecular features of EOCRC cancer in the Hispanic/Latino population; reveals potential avenues for tailored precision medicine therapies; and emphasizes the importance of multi-omics approaches in studying colorectal carcinogenesis. We expect this data to help contribute towards reducing cancer health disparities. Significance This study offers multi-omics profiling analysis of early-onset colorectal cancer (EOCRC) in an underserved community, explores the implications of MYC gene and WNT pathway alterations, and provides critical insights into cancer health disparities. ABSTRACT(short version) Colorectal cancer (CRC) has risen at an alarming rate in early-onset (<50 yrs) cases. Both its increased incidence and higher rates of mortality are especially pronounced within the Hispanic/Latino population. Although the MYC gene and WNT signaling pathway are well-established in CRC, we lack sufficient data about what role these elements play in young Hispanic/Latino patients. Here, we assess how both the MYC gene and WNT pathway are altered in Hispanic/Latino patients with early-onset CRC. We analyzed 30 early-onset and 37 late-onset CRC samples using multi-omics approaches, including DNA exome and RNA sequencing. The strategy allowed us to identify significant differences between early and late-onset tumors. Specifically, early-onset CRC had prevalent alterations in WNT pathway genes : APC, TCF7L2, DKK1, DKK2 , and FZD10 . Unique mutational profiles were linked to a high proportion of Peruvians-from-Lima-like (1KG-PEL-like) genetic similarity. These findings highlight the need for targeted precision medicine approaches to address the distinct molecular characteristics of early-onset CRC in underrepresented populations.
Year:
2024
Colorectal cancer contributes to cancer-related deaths and health disparities in the Hispanic and Latino community. To probe both the biological and genetic bases of the disparities, we characterized features of colorectal cancer in terms of somatic alterations and genetic similarity. Specifically, we conducted a comprehensive genome-scale analysis of 67 Hispanic and Latino samples. We performed DNA exome sequencing for somatic mutations, somatic copy number alterations, and genetic similarity. We also performed RNA sequencing for differential gene expression, cellular pathways, and gene fusions. We analyzed all samples for 22 important CRC gene mutations, 8 gene amplifications, and 25 CRC gene fusions. Then, we compared our data from the Hispanic and Latino samples to publicly available, Non-Hispanic White (NHW) cohorts. According to our analyses, twenty-four percent of colorectal carcinomas were hypermutated when patients were of Peruvians-from-Lima-like (1KG-PEL-like) genetic similarity population from the 1000 genome project. Moreover, most of these cases occurred in patients who were less than fifty years old age at diagnosis. Excluding hypermutated tumors, approximately 55% of colon cancers and 58% of rectum cancers exhibited two similar features: 1) the patterns of genomic alterations; 2) percentage of 1KG-PEL-like. We analyzed all samples -- which had a median 1KG-PEL-like proportion of 55% -- for 22 important CRC gene mutations, 8 gene amplifications, and 25 CRC gene fusions. One notable example of a frequently observed gene mutation was SMAD4. Samples with SMAD4 alterations, which are known to support tumor growth and progression, had the highest 1KG-PEL-like proportion (63%). According to our results from risk association analyses and differential gene expression, SMAD4 alterations were significant when we compared Hispanic and Latino samples to NHW cohorts. Of the 8 drug-targetable amplifications, PIK3CA and PI3K exhibited an average 1KG-PEL-like of over 55%. Of the 25 relevant CRC gene fusions, targetable genes included ALK, FGFR1, RAF1, and PTPRK; PTPRK was observed in a sample with the highest 1KG-PEL-like proportion (95%). Using integrative analysis, we also detected recurrent alterations in the WNT, TGFB, TP53, IGF2/PI3K, and RTK/RAS pathways. Importantly, these alterations mostly occurred in young patients with high 1KG-PEL-like. These findings highlight the potential for tailoring precision medicine therapeutics to an underrepresented population. Our study advances the molecular profiling of CRC in Hispanics and Latinos. In toto, genetic similarity appears to be an important component in understanding colorectal carcinogenesis and has the potential to advance cancer health disparities research. Significance Our study provides molecular profiles of colorectal cancer in an underserved community, probes the impact of genetic similarity, and sheds light on cancer health disparities. This study provides a comprehensive, genome-scale analysis of colorectal cancers (CRCs) taken from 67 Hispanic and Latino patients. We performed DNA exome sequencing for somatic mutations, somatic copy number alterations, and genetic similarity. We also performed RNA sequencing for differential gene expression, cellular pathways, and gene fusions. Our data from the Hispanic and Latino samples was compared to publicly available, Non-Hispanic White cohorts. In general, colorectal carcinomas from our cohort presented a high proportion (55%) of Peruvians-from-Lima-like (1KG-PEL-like) population from the 1000 genome project. Moreover, hypermutated colorectal carcinomas (24% of cases) predominantly occurred in individuals with 1KG-PEL-like. Most hypermutated cases occurred in young (<50) patients. We assessed our cohort for 22 important CRC gene mutations, 8 gene amplifications, and 25 CRC gene fusions. We cross-referenced results with percentage of 1KG-PEL-like. For example, frequent mutations were observed in a tumor suppressor called SM
Year:
2024
Variant selection for validation studies. Flow chart for variant prioritization for validation studies is shown for TP53 mutation associations ( A ) and PIK3CA mutation associations ( B ). Variants were first filtered by P values, MAF, and location near relevant GWAS loci. Variants were then filtered by ORs, location relative to gene with role in breast cancer, TP53 or PI3K/AKT pathway and then by RegulomeDB score. Variants are only counted once but may fall within one or more categories.
Year:
2024
Variant selection for validation studies. Flow chart for variant prioritization for validation studies is shown for TP53 mutation associations ( A ) and PIK3CA mutation associations ( B ). Variants were first filtered by P values, MAF, and location near relevant GWAS loci. Variants were then filtered by ORs, location relative to gene with role in breast cancer, TP53 or PI3K/AKT pathway and then by RegulomeDB score. Variants are only counted once but may fall within one or more categories.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (44)
Eric Singer
Professor
The Ohio State University Wexner Medical Center
Jiangjiang Zhu
Ohio State University
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Gregory Riedlinger
Rutgers Cancer Institute of New Jersey
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Nicholas Denko
Professor
Ohio State University
Qiang Hu
Roswell Park Comprehensive Cancer Center
Heinz-Josef Lenz
University of Southern California
Aik Choon Tan
Senior Director of Data Science
Huntsman Cancer Institute
Tanish Gandhi
Ohio State University
Lei Wei
Assistant Professor
Roswell Park Comprehensive Cancer Center
Julie R Palmer
Boston University School of Medicine
Weang Kee Ho
Professor
Sunway University
Wei Zheng
-
Ning Jin
Associate Proffessor
Ohio State University
Martin D. McCarter
Professor
University of Colorado Anschutz Medical Campus
Mariana C. Stern
Professor
University of Southern California
Carlos HF Chan
Emory University
David W. Craig
Professor
University of Southern California
Matthew Kalady
Professor
Ohio State University
Elad Ziv
Professor
University of California
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Bodour Salhia
University of Southern California
GUOCHONG JIA
Vanderbilt University
Rebecca Dodd
Assistant Professor
The University of Iowa
Gabriel Tinoco
Associate Professor of Medicine
Ohio State University
Dezheng Huo
University of Chicago
Anjun Ma
Assistant Professor
Ohio State University
Sheetal Hardikar
University of Utah
Qin Ma
Vice Chair for Research
Ohio State University
Yousef Zakharia
Mayo Clinic Arizona
Dan Spakowicz
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Daniel W. Rosenberg
University of Connecticut Health Center
Xiaokui Mo
Research Scientist
Ohio State University
Nereida Sotelo
Ohio State University
David Craig
Clinical Professor
University of Southern California
Charité Ricker
Assistant Professor of Clinical Medicine/Genetic Counselor
University of Southern California
Amber Aeilts
Assistant Professor, Genetic Counselor
Ohio State University
Ahmad Tarhini
Senior Member, Professor
H Lee Moffitt Cancer Center and Research Institute
Enrique Velazquez-Villarreal
Assistant Professor
City of Hope
Valentina Robila
Virginia Commonwealth University
Caroline Dravillas
Ohio State University
YunZhou Liu
Ohio State University
Amanda Toland
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.